login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Catheter-based ultrasound technology lower resistant hypertension, SOUND ITV study shows


Wednesday, 15 Aug 2012 11:36
Vivek Reddy
Vivek Reddy


On 14 August, Sound Interventions released three-month data from the company’s first-in-human clinical study (SOUND-ITV) to treat resistant hypertension through the use of catheter-based ultrasound.  


In addition to office-based blood pressure measurements, patients in the study underwent 24-hour ambulatory blood pressure monitoring prior to the ultrasonic renal denervation procedure, and subsequently three months after the procedure. The office-based blood pressure measurement results showed an average decrease of -25.6/-12.5 mm Hg. Consistent with these results the 24-hour mean blood pressure decreased by -23.1/-11.9 mm Hg.

Patients were treated at Holmolka Hospital in Prague, Czech Republic. Patients enrolled in the study were selected based on a history of hypertension which could not be controlled with medical therapy. The SOUND-ITV study was designed to evaluate the safety and effectiveness of the company’s volumetric dosimetry-controlled application of unfocused ultrasound (patents pending).


“These results demonstrate the ability of Sound Interventions’ ultrasound technology to significantly lower blood pressure in patients whose blood pressure was unable to be controlled by conventional pharmaceutical therapy,” said Petr Neuzil, chairman, Department of Cardiology of Holmolka Hospital.


Vivek Reddy, Mt Sinai Medical Center in New York City who collaborated with Neuzil and who is an advisor to Sound Interventions, commented: “The use of 24-hour monitoring to assess results of renal denervation procedures is a more accurate measurement of effectiveness than office-based blood pressure. The favorable results seen on the ambulatory blood pressure monitoring fortify our confidence in the efficacy of this technology.”


“These results, demonstrate the efficacy of Sound Interventions ultrasound dosimetry-controlled approach to renal denervation. Prior to initiation of the SOUND-ITV study, the company performed extensive in-vitro and in-vivo testing in order to perfect the ultrasound dosimetry. The pre-clinical testing has demonstrated that the Sound Interventions technology is unique in its ability to ablate the target nerve fibers while sparing the arterial wall,” said David Smith, president and CEO of Sound Interventions. “The success of the acute procedures in the SOUND-ITV study, along with these very strong clinical results validate this research and indicate that we are well on the way to developing the state-of-the-art renal denervation technology.”


Results of the SOUND-ITV study will be presented at the upcoming TCT 2012 Conference (Miami, USA, 22–26 October 2012).




Add New Comment

Related Items


Most popular


Friday, 22 Aug 2014
Royal Philips has announced that it has received 510(k) clearance from the US Food and Drug Administration to market its precision planning application for transcatheter aortic-valve implantation (TAV... FDA 510(k) clearance for TAVI precision treatment planning application

Joint consensus on antithrombotic use in AF patients with acute coronary syndrome published
Wednesday, 27 Aug 2014
A new European joint consensus document on the use of antithrombotic drugs in patients with atrial fibrillation presenting with an acute coronary syndrome and undergoing percutaneous coronary ... Joint consensus on antithrombotic use in AF patients with acute coronary syndrome published

No severe paravalvular leak with Acurate Neo TF
Monday, 29 Sep 2014
Data presented at PCR London Valves (28–30 September, London, UK) indicate that the Acurate Neo transfemoral TAVI system, which recently received the CE mark, is not associated with any incidences of ... No severe paravalvular leak with Acurate Neo TF

Features


The promise of chemical renal denervation
Friday, 05 Sep 2014
Tim A Fischell writes that chemical renal denervation using ethanol may have numerous advantages over energy-based “burning” technologies. The promise of chemical renal denervation

Drug-coated balloons for the management of coronary artery disease
Thursday, 04 Sep 2014
Robert Byrne writes that although drug-coated balloon therapy has been a significant innovation with relevance for everyday practice, convincing data in the coronary arena exists thus far only for ... Drug-coated balloons for the management of coronary artery disease

Profiles


Azeem Latib
Wednesday, 24 Sep 2014
Azeem Latib (senior interventional cardiologist, San Raffaele Hospital and EMO-GVM Centro Cuore C... Azeem Latib

David J Cohen
Wednesday, 04 Jun 2014
David J Cohen, director, Cardiovascular Research, Saint Luke’s Mid America Heart Institute, Kansas C... David J Cohen

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions